XML 52 R35.htm IDEA: XBRL DOCUMENT
v3.24.0.1

Revenue from contracts with customers (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2023
Summary of disaggregates revenues by major revenue streams | The following table disaggregates Teva’s revenues by major revenue streams. For additional information on disaggregation of revenues, see note 19.
|  | Year ended December 31, 2023 |
|  | North America |  |  | Europe |  |  | International Markets |  |  | Other activities |  |  | Total |
|  | (U.S.$ in millions) |
Sale of goods |  |  | 5,944 |  |  |  | 4,631 |  |  |  | 1,840 |  |  |  | 565 |  |  |  | 12,979 |
Licensing arrangements * |  |  | 601 |  |  |  | 51 |  |  |  | 24 |  |  |  | 5 |  |  |  | 681 |
Distribution |  |  | 1,577 |  |  |  | § |  |  |  | 38 |  |  |  | — |  |  |  | 1,615 |
Other** |  |  | 2 |  |  |  | 155 |  |  |  | 56 |  |  |  | 357 |  |  |  | 570 |
|  | $ | 8,124 |  |  | $ | 4,837 |  |  | $ | 1,958 |  |  | $ | 926 |  |  | $ | 15,846 |
* | Revenues from licensing arrangements in North America segment were mainly comprised of $500 million upfront payment received in connection with the collaboration on Teva’s anti-TL1A asset. See note 2.
** | “Other” revenues in Europe segment mainly related to the sale of certain product rights.
§ | Represents an amount less than $ 0.5 million.
|  | Year ended December 31, 2022 |
|  | North America |  |  | Europe |  |  | International Markets |  |  | Other activities |  |  | Total |
|  | (U.S.$ in millions) |
Sale of goods |  |  | 5,834 |  |  |  | 4,455 |  |  |  | 1,806 |  |  |  | 671 |  |  |  | 12,766 |
Licensing arrangements |  |  | 139 |  |  |  | 51 |  |  |  | 19 |  |  |  | 4 |  |  |  | 212 |
Distribution |  |  | 1,471 |  |  |  | 1 |  |  |  | 46 |  |  |  | — |  |  |  | 1,519 |
Other |  |  | 8 |  |  |  | 18 |  |  |  | 33 |  |  |  | 370 |  |  |  | 428 |
|  | $ | 7,452 |  |  | $ | 4,525 |  |  | $ | 1,903 |  |  | $ | 1,045 |  |  | $ | 14,925 |
|  | Year ended December 31, 2021 |
|  | North America |  |  | Europe |  |  | International Markets |  |  | Other activities |  |  | Total |
|  | (U.S.$ in millions) |
Sale of goods |  |  | 6,394 |  |  |  | 4,807 |  |  |  | 1,889 |  |  |  | 739 |  |  |  | 13,829 |
Licensing arrangements |  |  | 92 |  |  |  | 50 |  |  |  | 13 |  |  |  | 4 |  |  |  | 160 |
Distribution |  |  | 1,323 |  |  |  | 1 |  |  |  | 65 |  |  |  | — |  |  |  | 1,390 |
Other |  |  | (1) |  |  |  | 27 |  |  |  | 65 |  |  |  | 408 |  |  |  | 500 |
|  | $ | 7,809 |  |  | $ | 4,886 |  |  | $ | 2,032 |  |  | $ | 1,151 |  |  | $ | 15,878 |
Summary of Sales Reserves and Allowances | SR&A to U.S. customers comprised approximately 65% of the Company’s total SR&A as of December 31, 2023, with the remaining balance primarily in Canada and Germany. The changes in SR&A for third-party sales for the years ended December 31, 2023 and 2022 were as follows:
|  | Sales Reserves and Allowances |
|  | Reserves included in Accounts Receivable, net |  |  | Rebates |  |  | Medicaid and other governmental allowances |  |  | Chargebacks |  |  | Returns |  |  | Other |  |  | Total reserves included in Sales Reserves and Allowances |  |  | Total |
|  | (U.S.$ in millions) |
Balance at January 1, 2023 |  | $ | 67 |  |  | $ | 1,575 |  |  | $ | 663 |  |  | $ | 991 |  |  | $ | 455 |  |  | $ | 66 |  |  | $ | 3,750 |  |  | $ | 3,817 |
Provisions related to sales made in current year period |  |  | 354 |  |  |  | 4,015 |  |  |  | 654 |  |  |  | 7,579 |  |  |  | 264 |  |  |  | 109 |  |  |  | 12,621 |  |  |  | 12,975 |
Provisions related to sales made in prior periods |  |  | — |  |  |  | (31 | ) |  |  | (33 | ) |  |  | (54 | ) |  |  | 17 |  |  |  | — |  |  |  | (101 | ) |  |  | (101 | )
Credits and payments |  |  | (360 | ) |  |  | (3,974 | ) |  |  | (748 | ) |  |  | (7,662 | ) |  |  | (304 | ) |  |  | (77 | ) |  |  | (12,765 | ) |  |  | (13,125 | )
Translation differences |  |  | — |  |  |  | 18 |  |  |  | 4 |  |  |  | 5 |  |  |  | 4 |  |  |  | (1 | ) |  |  | 30 |  |  |  | 30 |
Balance at December 31, 2023 |  | $ | 61 |  |  | $ | 1,603 |  |  | $ | 540 |  |  | $ | 859 |  |  | $ | 436 |  |  | $ | 97 |  |  | $ | 3,535 |  |  | $ | 3,596 |
|  | Sales Reserves and Allowances |
|  | Reserves included in Accounts Receivable, net |  |  | Rebates |  |  | Medicaid and other governmental allowances |  |  | Chargebacks |  |  | Returns |  |  | Other |  |  | Total reserves included in Sales Reserves and Allowances |  |  | Total |
|  | (U.S.$ in millions) |
Balance at January 1, 2022 |  | $ | 68 |  |  | $ | 1,655 |  |  | $ | 854 |  |  | $ | 1,085 |  |  | $ | 535 |  |  | $ | 112 |  |  | $ | 4,241 |  |  | $ | 4,309 |
Provisions related to sales made in current year period |  |  | 363 |  |  |  | 3,823 |  |  |  | 871 |  |  |  | 7,819 |  |  |  | 317 |  |  |  | 85 |  |  |  | 12,915 |  |  |  | 13,278 |
Provisions related to sales made in prior periods |  |  | — |  |  |  | (69 | ) |  |  | (35 | ) |  |  | (44 | ) |  |  | (3 | ) |  |  | (51 | ) |  |  | (202 | ) |  |  | (202 | )
Credits and payments |  |  | (364 | ) |  |  | (3,798 | ) |  |  | (1,023 | ) |  |  | (7,861 | ) |  |  | (390 | ) |  |  | (77 | ) |  |  | (13,149 | ) |  |  | (13,513 | )
Translation differences |  |  | — |  |  |  | (36 | ) |  |  | (4 | ) |  |  | (8 | ) |  |  | (4 | ) |  |  | (3 | ) |  |  | (55 | ) |  |  | (55 | )
Balance at December 31, 2022 |  | $ | 67 |  |  | $ | 1,575 |  |  | $ | 663 |  |  | $ | 991 |  |  | $ | 455 |  |  | $ | 66 |  |  | $ | 3,750 |  |  | $ | 3,817 |

X
- Definition Tabular disclosure of sales reserves and allowances current. + References No definition available. + Details
Name: | teva_SalesReservesAndAllowancesCurrentTableTextBlock
Namespace Prefix: | teva_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration